Company:  BEIGENE, LTD. (BGNE)
Form Type:  4
Filing Date:  3/20/2017 
CIK:  0001651308 
Address:  C/O MOURANT OZANNES CORPORATE SERVICES
94 SOLARIS AVENUE, CAMANA BAY
 
City, State, Zip:  GRAND CAYMAN,  KY1-1108 
Telephone:  13459494123 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$85.14  
Change: 
2.37 (2.86%)  
Trade Time: 
04:00 PM EST  
Market Cap: 
$44.29B
Trade BGNE now with 

© 2017  
Description of Business
We are a globally focused, clinical-stage biopharmaceutical company dedicated to becoming a leader in the discovery and development of innovative, molecularly targeted and immuno-oncology drugs for the treatment of cancer. We believe the next generation of cancer treatment will utilize therapeutics both as monotherapies and in combination to attack multiple underlying mechanisms of cancer cell growth and survival. We further believe that discovery of next-generation cancer therapies requires new research tools. To that end, we have developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support our drug discovery effort. Our strategy is to develop a pipeline of drug candidates with the potential to be best-in-class monotherapies and also important components of multiple-agent combination regimens.
Register and access this filing in:     
  FORM 4
    NAME AND TITLE
    NON DERIVATIVE SECURITIES
    DERIVATIVE SECURITIES
    EXPLANATIONS AND REMARKS
    REPORTING OWNERS
    SIGNATURES